TRIPHAGE PG2 Tablet is a powerful combination therapy for the effective management of Type 2 Diabetes Mellitus (T2DM). Developed and manufactured by BluepillExpress, a leader in third-party pharmaceutical manufacturing and global export solutions, this triple drug combination includes:
Glimepiride (2 mg): A sulfonylurea that increases pancreatic insulin secretion.
Metformin Hydrochloride (500 mg/850 mg/1000 mg): A biguanide that decreases hepatic glucose output and improves insulin sensitivity.
Pioglitazone (15 mg): A thiazolidinedione that enhances peripheral glucose uptake by improving insulin sensitivity.
This synergistic formula targets multiple pathophysiological mechanisms of T2DM and is ideal for patients who require multi-modal glycemic control.
Manufacturing Excellence – BluepillExpress
TRIPHAGE PG2 Tablet is produced in WHO-GMP, ISO 9001:2015, and Schedule M certified facilities, using validated processes and premium-quality active pharmaceutical ingredients (APIs). Our state-of-the-art machinery ensures:
Consistent batch uniformity
Accurate tablet weight and dosage precision
Controlled-release mechanisms (where applicable)
Advanced blister/alu-alu packaging for extended shelf life
Every batch of TRIPHAGE PG2 undergoes rigorous quality control and quality assurance testing, including:
Dissolution and disintegration profiling
Uniformity of content and weight variation
Microbial limit testing
Stability studies
Therapeutic Indications:
TRIPHAGE PG2 is indicated for:
Management of Type 2 Diabetes Mellitus (non-insulin dependent)
Patients uncontrolled on dual therapy (Metformin + Glimepiride or Pioglitazone)
Glycemic control in obese or insulin-resistant diabetic patients
Delaying the progression of diabetic complications like nephropathy, neuropathy, and retinopathy
Pharmacological Action:
Glimepiride: Stimulates pancreatic beta-cells to release insulin; effective in postprandial glucose control.
Metformin: Suppresses hepatic gluconeogenesis and enhances insulin sensitivity in muscles.
Pioglitazone: Activates PPAR-γ receptors, improving insulin response in adipose tissue, liver, and muscle.
This triple-action ensures comprehensive glycemic control across fasting, postprandial, and insulin-resistance parameters.
Dosage & Administration:
The usual starting dose is:
One tablet once or twice daily, with meals, depending on the patient’s current blood sugar levels, renal function, and physician’s guidance.
Dosage should be titrated carefully under medical supervision, especially in patients with renal or hepatic impairment.
Product Strengths & Variants (Commonly Manufactured):
Glimepiride 2 mg + Metformin 1000 mg + Pioglitazone 15 mg
Glimepiride 2 mg + Metformin 500 mg + Pioglitazone 15 mg
Customized compositions as per buyer's requirements
Export-Ready Packaging by BluepillExpress:
TRIPHAGE PG2 is packed in:
Alu-Alu or Blister Pack (10x10 tablets)
Multilingual labelling for regulatory compliance
Moisture-resistant outer cartons for extended shelf life
Country-specific branding and design support
BluepillExpress provides complete documentation for international distribution, including:
Certificate of Analysis (COA)
Stability Data
Certificate of Pharmaceutical Product (COPP)
CTD/eCTD dossiers on request
Precautions & Warnings:
Regular monitoring of renal function (especially due to Metformin)
Avoid in hepatic impairment or active heart failure (due to Pioglitazone)
Hypoglycemia risk if used with alcohol or missed meals
Not suitable for Type 1 Diabetes or diabetic ketoacidosis
Common Side Effects:
Gastrointestinal discomfort (nausea, bloating)
Weight gain (due to Pioglitazone)
Hypoglycemia (especially in fasting or elderly patients)
Edema or fluid retention
Why Choose TRIPHAGE PG2 by BluepillExpress?
Superior triple-drug control for complex diabetic cases
Cost-effective option for developing markets
Globally compliant third-party production and export
Flexible branding and bulk manufacturing options
Backed by years of therapeutic success and safety
Description provided by bluepill express.
FIEO Registered
Export Ready
